drugset / Trial / NCT00245362
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and effectiveness of CG8020 and CG2505.
Timeline
- Start
- 2002-06
- Primary completion
- —
- Completion
- 2004-06